Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. [electronic resource]
Producer: 20140519Description: 2200-12 p. digitalISSN:- 1538-8514
- Apoptosis -- drug effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- Drug Resistance, Neoplasm -- drug effects
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Mutation
- Niclosamide -- administration & dosage
- Phosphorylation -- drug effects
- Proto-Oncogene Proteins c-bcl-2 -- genetics
- Quinazolines -- administration & dosage
- STAT3 Transcription Factor -- biosynthesis
- Signal Transduction -- drug effects
- Xenograft Model Antitumor Assays
- bcl-X Protein -- biosynthesis
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.